PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.313
https://www.valueinhealthjournal.com/article/S1098-3015(19)32691-9/fulltext
Title :
PCN116 COST-EFFECTIVENESS OF PEMBROLIZUMAB (KEYTRUDA®) PLUS PLATINUM-PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER IN FRANCE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32691-9&doi=10.1016/j.jval.2019.09.313
First page :
Section Title :
Open access? :
No
Section Order :
10252